US Stem Cell Inc (USRM)

[Zues]

USRM (board) had viewed pursuing RMAT as a waste of time and money at this juncture (no guidelines for commercialization). Yes, you are most likely correct that the FDA asked for more info, but USRM said enough is enough. USRM has a responsibility to generate revenue. Paying FDA fees over and over does not accomplish this. Q2 is around the corner. Q2 matters.

There are a number of things in play:

Clinic revenues
Gottlieb's influence
FDA guidelines TBD
Other states following Texas
Buyout? (it could happen down the road)

People will forget about RMAT and the FDA once they see revenues from the clinics. It's about making people better and making money while doing it.